Affordable Access

deepdyve-link
Publisher Website

Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma.

Authors
  • Santoni, Matteo1
  • Heng, Daniel Y C2
  • Aurilio, Gaetano3
  • Iozzelli, Andrea4
  • Servi, Lucilla5
  • Fabiani, Andrea5
  • Giannini, Massimo6
  • Mazzucchelli, Roberta7
  • Cimadamore, Alessia7
  • Scarpelli, Marina7
  • Zaghloul, Mohamed S8
  • Battelli, Nicola1
  • Montironi, Rodolfo7
  • 1 Oncology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy. , (Italy)
  • 2 Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada. , (Canada)
  • 3 IEO, European Institute of Oncology IRCCS, Medical Division of Urogenital and Head & Neck Cancer, Milan, Italy. , (Italy)
  • 4 Radiology Unit, Macerata Hospital, via Santa Lucia 2, Macerata, Italy. , (Italy)
  • 5 Urology Unit, Macerata Hospital, Via Santa Lucia 2, Macerata, Italy. , (Italy)
  • 6 UOC Radioterapia Oncologica, Macerata Hospital, via Santa Lucia 2, Macerata, Italy. , (Italy)
  • 7 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. , (Italy)
  • 8 Radiotherapy Department, National Cancer Institute, Cairo University & Children's Cancer Hospital Egypt (CCHE), Cairo, Egypt. , (Egypt)
Type
Published Article
Journal
Current drug targets
Publication Date
Jan 01, 2020
Volume
21
Issue
4
Pages
416–423
Identifiers
DOI: 10.2174/1389450120666191017113051
PMID: 31625471
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Radiotherapy is considered a second life in Renal Cell Carcinoma (RCC) patients, mainly due to the introduction of immune checkpoint inhibitors, such as anti-Programmed-death (PD)-1, alone or in combination with anti-Cytotoxic T-Lymphocyte Antigen (CTLA)-4. Several trials are investigating the efficacy/safety of immune checkpoint inhibitors in sequential or combined strategies with radiotherapy. Chimeric Antigen Receptor (CAR)-T cells therapy as a promising approach in cancer patients has opened the way to novel possibilities of integrating therapies. The identification of biomarkers of tumor response to these combinations represents a challenge in RCC, together with the research for the best partner for immunotherapy in metastatic patients. In this review we illustrated preclinical/clinical data on the integration of radiotherapy with immunocheckpoint inhibitors or CART cells in RCC. Copyright© Bentham Science Publishers; For any queries, please email at [email protected]

Report this publication

Statistics

Seen <100 times